편두통 예방에서 토피라메이트와 연관된 인지기능장애 = Topiramate Related Cognitive Dysfunction during Migraine Prevention

다국어 초록 (Multilingual Abstract)

Background: Topiramate (TPM), a broad-spectrum antiepileptic drug, has recently been demonstrated to be effective as a monotherapeutic device for migraine prevention. We investigated the impact of TPM on cognition during migraine prevention.
Methods: Twenty-eight migraineurs were evaluated. They were instructed to take 25 mg of TPM per day, with 25 mg weekly increments to a maximum of 100 mg per day according to the therapeutic responsiveness. We assessed cognitive dysfunctions by spontaneous patient reports and several neuropsychological tests comparing the baseline and at 3 months during on-treatment. We also compared these tests to age, sex, education, clinical features of migraine, TPM dose, and global effectiveness.
Results: After 3 months of therapy, 21 patients undertook a follow-up neuropsychological test. Even though headache frequency, severity, and disability were significantly decreased in a follow-up period, there was a significant impairment in backward digit span (P=.006) and verbal fluency (P=.023). Thirteen patients (62%) showed an impaired backward digit span, and 11 patients (52%) exhibited an impaired verbal fluency. Five patients (24%) complained of symptoms associated with these impairments. Cognitive impairments were well correlated to the frequency of migraine attack, higher daily TPM dose, and global effectiveness. In six patients who showed the impairment of both items, TPM was withdrawn and their cognition was retested after 2 weeks. There was a significant improvement in these cognitive functions.
Conclusions: TPM appears to exert a dose-related, strong negative influence on working memory and verbal fluency during migraine prevention. It can be related to drug tolerability.

참고문헌 (Reference)

1 "Topiramate in the preventive treatment of episodic migraine:a combined analysis from pilot,double-blind,placebo-controlled trials" 8 : 428-432, 2003

2 "Topiramate in migraine prevention" 61 : 490-495, 2004

3 "Topiramate in clinical practice:long-term experience in patients with refractory epilepsy referred to tertiary epilepsy center" 5 : 380-387, 2004

4 "Topiramate for migraine prevention:a randomized controlled trial" 291 : 965-973, 2004

5 "Topiramate and word-finding difficulties in patients with epilepsy" 60 : 1104-1107, 2003

6 "The effects of adjunctive topiramate on cognitive function in patients with epilepsy" 44 : 339-347, 2003

7 "Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients" 54 : 171-178, 2003

8 "Prevalence of migraine in Korean adults:A nationwide survey" 1 : 57-66, 2000

9 "Postmarketing experience with topiramate and cognition" 42 : 1134-1140, 2001

10 "Migraine patients experience poorer subjective well-being/quality of life even between attacks" 15 : 31-36, 1995

11 "Migraine and cognitive function:a life-course study" 59 : 904-908, 2002

12 "Medical consultation for migraine:results from the American Migraine Study" 38 : 87-96, 1998

13 "Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders" 7 1-96, cephalalgia1988

14 "Effects of topiramate on cognitive function" 69 : 636-641, 2000

15 "Duke University Center for Clinical Health Policy Research Drug Treatments for the Prevention of Migraine Headache Department of Commerce" 1999

16 "Differential cognitive and behavioral effects of topiramate and valproate" 60 : 1483-1488, 2003

17 "Cognitive disturbances and regional cerebral blood flow abnormalities in migraine patients:their relationship with the clinical manifestations of the illness" 22 : 291-302, 2002

18 "Cognitive and behavioural assessment in clinical trials" 155-157,

19 "Cognitive and behavioural assessment in clinical trials" 159-161,

20 "Clinical utility of an instrument assessing migraine disability" 854-861, headache2001

21 "Burden of migraine in the United States:disability and economic costs" 159 : 813-818, 1999

22 "Auditory naming and temporal lobe epilepsy" 35 : 229-243, 1999

23 "Acquired transient stuttering during a migraine attack" 40 : 170-172, 2000

24 "A multicenter,randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures" 41 : 1167-1178, 2000